Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03386474 (CRTH258A2301E1) Neovascular age-related macular degeneration (nAMD) Phase 3 NCT04005352 TALON (CRTH258A2303) Neovascular Age-related Macular Degeneration (nAMD) Phase 3B 150 Number of treatment-emergent adverse events Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study Average change in Best-corrected visual acuity Distribution of the last interval with no disease activity (in a Treat-to-Control regimen) Arm 1: Brolucizumab 6 mg intravitreal injection Arm 2: Aflibercept 2 mg intravitreal injection Patients with Neovascular Age-related Macular Degeneration (nAMD) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment Target Patients Read-out Milesstone(s) 2018 (actual) Publication Manuscript planned for submission H2-2021 95 Investor Relations | Q3 2021 Results 2022 TBD NOVARTIS | Reimagining Medicine

View entire presentation